Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

SCLC cell line profiling on 100K arrays

ABSTRACT: Twenty three small-cell lung carcinoma (SCLC) cell lines from ATCC profiled on 100K genotyping arrays Keywords: comparative genomic hybridization

ORGANISM(S): Homo sapiens

PROVIDER: GSE7068 | GEO | 2007/04/15

SECONDARY ACCESSION(S): PRJNA98471

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Genotyping of human SCLC cell line profiling on 100K arrays

Project description:Twenty three small-cell lung carcinoma (SCLC) cell lines from ATCC profiled on 100K genotyping arrays Experiment Overall Design: The cell lines were run on 100K SNP genotyping arrays to obtain copy number information

2008-06-15 | E-GEOD-7068 | biostudies-arrayexpress

Copy number profiling of 36 human melanoma tumors on Affymetrix 100K SNP arrays

Project description:Fresh frozen Melanoma patient samples were profiled on Affymetrix GeneChip Mapping 100K Set Arrays

2013-10-15 | GSE41592 | GEO

Copy number profiling of 36 ovarian tumors on Affymetrix 100K SNP arrays and 16 ovarian tumors on 500K SNP arrays

Project description:Copy number profiling of 36 ovarian tumors on Affymetrix 100K SNP arrays Thirty-six ovarian tumors were profiled for copy-number alterations with the Affymetrix 100K Mapping Array. Copy number profiling of 36 ovarian tumors on Affymetrix 500K SNP arrays Sixteen ovary tumors were profiled for copy-number alterations with the high-resolution Affymetrix 500K Mapping Array.

2010-12-16 | GSE26075 | GEO

100K Food Pathogen Project

Project description:100K Food Pathogen Project

| PRJNA186441 | ENA

Copy number profiling of 45 human breast cancer cell lines on Affymetrix 100K SNP arrays

Project description:Breast cancer cell lines grown in full serum under standard conditions were profiled on Affymetrix GeneChip Mapping 100K Set Arrays Keywords: Mapping Array

2009-04-22 | GSE13696 | GEO

Affymetrix 100K SNP array data-

Project description:allele call files from analysis of NCI60 cell line DNA on 100K SNP arrays. Keywords = NCI60, SNP array, cancer cell line Keywords: other

2005-07-02 | GSE2520 | GEO

Pancreatic cancer_Affymetrix 100K SNP arrays

Project description:To identify genomic abnormalities characteristic of pancreatic ductal adenocarcinoma (PDAC) in vivo, a panel of 27 microdissected PDAC specimens were analyzed using high-density microarrays representing ~116 000 single nucleotide polymorphism (SNP) loci. We detected frequent gains of 1q, 2, 3, 5, 7p, 8q, 11, 14q and 17q (>78% of cases), and losses of 1p, 3p, 6, 9p, 13q, 14q, 17p and 18q (>44%). Although the results were comparable with those from array CGH, regions of those genetic changes were defined more accurately by SNP arrays. Integrating the Ensembl public data, we have generated "gene" copy number indices that facilitate the search for novel candidates involved in pancreatic carcinogenesis. Copy numbers in a subset of the genes were validated using quantitative real-time PCR. The SKAP2/SCAP2 gene (7p15.2), which belongs to the src family kinases, was most frequently (63%) amplified in our sample set and its recurrent over-expression (67%) was confirmed by reverse transcription-PCR. Furthermore, fluorescence in situ hybridization and in situ RNA hybridization analyses for this gene have demonstrated a significant correlation between DNA copy number and mRNA expression level in an independent sample set (p<0.001). These findings indicate that the dysregulation of SKAP2/SCAP2, which is mostly caused by its increased gene copy number, is likely to be associated with the development of PDAC. Keywords: pancreatic cancer; tissue microdissection; SNP array; DNA copy number; LOH

2007-10-22 | GSE7130 | GEO

Copy number profiling of 36 human melanoma tumors on Affymetrix 100K SNP arrays

Project description:Fresh frozen Melanoma patient samples were profiled on Affymetrix GeneChip Mapping 100K Set Arrays Profiling of 36 melanoma tumors

2013-10-15 | E-GEOD-41592 | biostudies-arrayexpress

Comparative genomic hybridization of human breast cancer cell lines (45) on Affymetrix 100K SNP arrays

Project description:Breast cancer cell lines grown in full serum under standard conditions were profiled on Affymetrix GeneChip Mapping 100K Set Arrays Experiment Overall Design: Profiling of cell lines grown under standard conditions

2009-05-01 | E-GEOD-13696 | biostudies-arrayexpress

SCLC cell line profiling on HG-U133A arrays set 2

Project description:RNA expression analysis was performed to compare patterns to sensitivity to BCL2 inhibitors (ABT-263). Overexpression of the prosurvival Bcl-2 family members (Bcl-2, Bcl-xL and Mcl-1) is commonly associated with tumor maintenance, progression and chemoresistance. We previously reported the discovery of ABT-737, a potent, small molecule Bcl-2 family protein inhibitor. A major limitation of ABT-737 is that it is not orally bioavailable. This may limit its use for chronic single agent treatment and the flexibility to dose in combination with parenteral chemotherapy. Here we report the discovery and biological properties of ABT-263, a potent, orally bioavailable Bad-like BH3 mimetic (Kiâ??s of < 1 nM for Bcl-2, Bcl-xL and Bcl-w). The oral bioavailability of ABT-263 in preclinical animal models is 20% - 50%, depending on formulation. ABT-263 disrupts Bcl-2/Bcl-xL interactions with pro-death proteins (e.g., Bim) in cells leading to the initiation of apoptosis within 2 hr post-treatment. In human tumor cells, ABT-263 rapidly induces Bax translocation, cytochrome c release and subsequent programmed cell death. Oral administration of ABT-263 alone induces complete tumor regressions in xenograft models of small cell lung cancer and acute lymphoblastic leukemia. In xenograft models of aggressive B-cell lymphoma and multiple myeloma where ABT-263 exhibits modest or no single agent activity, it significantly enhances the efficacy of clinically relevant therapeutic regimens. These data provide the rationale for clinical trials evaluating ABT-263 in SCLC and B-cell malignancies. The oral efficacy of ABT-263 should provide dosing flexibility to maximize clinical utility as both a single agent and in combination with standard chemotherapeutic regimens. Keywords: cell line comparison

2008-05-01 | GSE10841 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data